share_log

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 EPS $(1.43) Vs $(1.51) YoY

Benzinga ·  Mar 5 08:21

NUVECTIS PHARMA, INC.STATEMENT OF OPERATIONS(USD in thousands, except per share and share amounts)For the year endedFor the year endedDecember 31, 2023December 31, 2022OPERATING EXPENSES:Research and development15,38013,227General and administrative7,5176,007OPERATING LOSS(22,897)(19,234)Finance income637149NET LOSS(22,260)(19,085)NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(22,260)(19,085)BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING(1.43)(1.51)Basic and diluted weighted average number of common shares outstanding15,556,65512,657,651

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment